Effects of 20-week Mat-Pilates & Dual-Task Training on Strength, Balance, Cognition, and Fall Risk in Older Adults
NCT07119762, Not applicable, Completed, Universidade do Porto
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of 20-week Mat-Pilates & Dual-Task Training on Strength, Balance, Cognition, and Fall Risk in Older Adults | ClinicalTrials.gov |
| NCT number | NCT07119762 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 67 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Universidade do Porto | ClinicalTrials.gov |
| Conditions | Healthy People Programs | ClinicalTrials.gov |
| Interventions | Pilates sections | ClinicalTrials.gov |
| First posted | 2025-08-13 | ClinicalTrials.gov |
| Last updated | 2026-10-27 | ClinicalTrials.gov |
Registered outcomes 19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Balance- Biodex balance System SD | Baseline, post 20 weeks. | The Biodex Balance System SD plataform was used to assess balance through the Sensory Integration Test (CTSIB) and the Falls Risk Test. These assessments evaluate how the central nervous system processes sensory inputs (visual, and proprioceptive systems) to maintain postural control, helping to identify balance impairments and fall risk (Biodex Medical Systems, Shirley, NY). | ClinicalTrials.gov |
| Primary | Stability of the trunk muscles- Stabilzer Pressure Biofeedback Unit | Baseline, post 20 weeks | The study by Grooms et al. (2013) evaluated trunk muscle stability using the Stabilizer Pressure Biofeedback Unit, a device that measures the activation of deep abdominal muscles during exercises. It helps ensure proper engagement of core stabilizers, such as the transversus abdominis and multifidus, making it useful for both assessment and rehabilitation. | ClinicalTrials.gov |
| Primary | Balance- Single-Leg Stance Test | Baseline, post 20 weeks. | The Single-Leg Stance Test is a simple and widely used method for assessing static postural balance. It involves standing on one leg, with eyes open, for up to 45 seconds. This test has been validated by Springer et al. (2007), who demonstrated its reliability in detecting balance deficits and fall risk, particularly in older adults and clinical populations. | ClinicalTrials.gov |
| Primary | Functional Fitness (Strength)- SFT | Baseline; 20 weeks (post-intervention); 36 weeks (after 16-week detraining); 56 weeks (after second 20-week intervention in a subgroup) | The Senior Fitness Test includes specific assessments for upper and lower body strength in older adults. Lower body strength is measured using the 30-second chair stand test, which evaluates leg strength and endurance. Upper body strength is assessed with the 30-second arm curl test, measuring arm muscle strength. These tests were validated by Rikli and Jones (1999) and are considered reliable indicators of functional fitness in elderly populations. | ClinicalTrials.gov |
| Primary | Functional Fitness (Flexibility)- SFT | Beseline, post 20 weeks. | The Senior Fitness Test includes two flexibility assessments aimed at older adults: the Sit and Reach Test, which evaluates lower body flexibility, particularly of the hamstrings and lower back; and the Back Scratch Test, which assesses upper body flexibility, focusing on shoulder mobility. Both tests were validated by Rikli and Jones (1999) and are widely used to detect limitations in functional range of motion. | ClinicalTrials.gov |
| Primary | Cardiorespiratory endurance- SFT | Baseline, post 20 weeks. | The 6-Minute Walk Test is part of the Senior Fitness Test and evaluates cardiorespiratory endurance in older adults. Participants are instructed to walk as far as possible in six minutes along a 50-meter rectangular course. This test was validated by Rikli and Jones (1999) and is considered an excellent indicator of functional capacity for daily activities, such as climbing stairs or performing household tasks. | ClinicalTrials.gov |
| Primary | Dynamic balance and agility- 8-Foot Up-and-Go Test | Baseline, post 20 weeks. | The 8-Foot Up-and-Go Test is part of the Senior Fitness Test and assesses agility and dynamic balance in older adults. The participant must stand up from a chair, walk 2.44 meters (8 feet) quickly, turn around a cone, and return to the seat as fast as possible (Rikli and Jones, 1999). | ClinicalTrials.gov |
| Primary | Handgrip strength | Baseline, 20 weeks. | Handgrip strength was assessed using the Jamar analog dynamometer (Sammons Preston Inc., Bolingbrook, Illinois, USA), a gold-standard instrument widely used to measure upper limb strength. The test is simple, quick, and provides a reliable indicator of overall functional strength. The Jamar dynamometer has well-established validity in clinical research. | ClinicalTrials.gov |
| Primary | Trunk strength- Biodex System 4 Pro isokinetic dynamometer | Baseline; 20 weeks (post-intervention); 36 weeks (after 16-week detraining); 56 weeks (after second 20-week intervention in a subgroup) | Trunk strength was assessed using the Biodex System 4 Pro isokinetic dynamometer (Biodex Medical Systems, Shirley, NY, USA), a highly accurate device used to measure muscular torque and power at various speeds. It is widely used in clinical and research settings to analyze muscular performance in a standardized and safe manner. | ClinicalTrials.gov |
| Secondary | Cognitive function- MoCA | Baseline, 20 weeks. | Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA), a brief and validated tool for screening mild cognitive impairment. The test evaluates multiple cognitive domains, including memory, attention, language, visuospatial abilities, and executive function. The MoCA is sensitive for detecting early cognitive decline in older adults (Nasreddine, Z. S., et al., 2005). | ClinicalTrials.gov |
| Secondary | Cognitive function- Trail Making Test | Baseline, 20 weeks. | Executive cognitive function was assessed using the Trail Making Test (TMT), parts A and B. Part A evaluates visual attention and processing speed, while part B measures cognitive flexibility and executive control, requiring alternating between numbers and letters. The TMT is widely used and validated for detecting cognitive impairment in older adults (Reitan, R. M., 1958). | ClinicalTrials.gov |
| Secondary | Cognitive function- Stroop Color and Word Test | Baseline, 20 weeks. | The Stroop Color and Word Test (SCWT) was employed to assess cognitive inhibition and selective attention. The test includes reading color words, naming ink colors, and naming ink colors when the word and ink are incongruent. This version follows Bickford et al. (2018) and is sensitive to detecting cognitive interference, making it valuable in clinical settings to identify executive dysfunction. | ClinicalTrials.gov |
| Secondary | General intelligence- Wechsler Adult Intelligence Scale (WAIS-III) | Baseline, 20 weeks | General intelligence was assessed using the WAIS-III, a standardized scale that measures various cognitive domains in adults, including verbal comprehension, perceptual reasoning, working memory, and processing speed. It is widely recognized for its validity and reliability in the assessment of intellectual functioning (Wechsler, D., 1997). | ClinicalTrials.gov |
| Secondary | Cognitive function- Memory function | Baseline, 20 weeks. | Memory function was assessed using the Wechsler Memory Scale (WMS), a validated tool that evaluates immediate and delayed memory, attention, and learning ability. It is commonly used in clinical settings to diagnose memory disorders and monitor cognitive changes over time (Wechsler, D., 1997). | ClinicalTrials.gov |
| Secondary | Sociodemographic questionnaire and and clinical characterization | Baseline, 20 weeks. | Sociodemographic questionnaire which includes the following variables: ID, group allocation, birth date, age, sex, education level, profession, number of falls, diagnosed diseases. Quality of life satisfaction will also be evaluated using self-report. | ClinicalTrials.gov |
| Secondary | Height assessment | Baseline, 20 weeks | Height was measured using the Seca 217 mobile stadiometer, with participants standing upright and barefoot. Measurements were recorded in centimeters. | ClinicalTrials.gov |
| Secondary | Body mass | Baseline, 20 weeks. | Body mass (kg), fat-free mass (kg), fat mass (kg) and BMI will be analyzed with bioimpedance (InBody 120®). | ClinicalTrials.gov |
| Secondary | Bone mineral density | Baseline; 20 weeks (post-intervention); 36 weeks (after 16-week detraining); 56 weeks (after second 20-week intervention in a subgroup) | Bone mineral density will be assessed by DEXA (Hologic QDR Explorer 4500, Bedford, MA, USA) at the lumbar spine and femoral neck. | ClinicalTrials.gov |
| Other | Habitual physical activityBaseline, 20 weeks. | Baseline, 20 weeks. | Habitual physical activity will be assessed using ActiGraph GT9X Link accelerometers worn for 7 consecutive days. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 2
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)